Ritonavir-boosted lopinavir plus nucleoside or nucleotide reverse transcriptase inhibitors versus ritonavir-boosted lopinavir plus raltegravir for treatment of HIV-1 infection in adults with virological failure of a standard first-line ART regimen (SECOND-LINE): a randomised, open-label, non-inferiority study
Year: 2013
Type: article
Study designs: Randomized Controlled Trial, Clinical Trial
Source: The Lancet
Author: *
Language: English
Subfield: Infectious Diseases
Field: Medicine
Domain: Health Sciences
Keywords: HIV-1 infection, second-line antiretroviral therapy, raltegravir, ritonavir-boosted lopinavir, nucleoside reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors, virological failure, non-inferiority, viral suppression, adverse events, gastrointestinal adverse effects, adults living with HIV
Open Access status: closed
Funder: University of New South Wales
OpenAlex ID: W2130068726
